

P&T Motion History Antidepressants

Drugs Reviewed	Motion	Date Reviewed	Scan Accepted as Adequate	Reiteration of Prior Motion	Decision
SSRI: citalopram escitalopram fluoxetine fluvoxamine paroxetine sertraline vilazodone vortioxetine SNRI/SSNRI: desvenlafaxine duloxetine levomilnacipran venlafaxine OTHER: bupropion mirtazapine nefazodone <i>trazadone</i>	<p>After considering the evidence of safety, efficacy and special populations for the treatment of major depressive disorder, dysthymia, seasonal affective disorder, subsyndromal depression, premenstrual dysphoric disorder, generalized anxiety disorder, obsessive compulsive disorder, panic disorder, and post-traumatic stress disorder in adults as well as major depressive disorder in the pediatric population</p> <p>I move that bupropion, citalopram, duloxetine, escitalopram, fluoxetine, sertraline, fluvoxamine, levomilnacipran, mirtazapine, paroxetine, desvenlafaxine, venlafaxine, vortioxetine and vilazodone are safe and efficacious for their approved indications. The Washington Preferred Drug List must include as preferred at least two SSRIs one of which must have an indication for pediatric and adolescent use, at least one SNRI or SSNRI, mirtazapine, and bupropion. The second generation antidepressants cannot be subject to therapeutic interchange in the Washington preferred drug list.</p> <p>Nefazodone is also efficacious for its approved indications but does have a higher risk of hepatic toxicity and so should not be a preferred drug on the PDL.</p> <p>Motion: Michael Johnson 2nd: Amber Figueroa</p>	April 19, 2017	NA	No	Passed unanimous

Bold = new this update

Grey italic = not part of PDL program

Grey = not reviewed, not eligible for PDL program

4/20/2017